Metagenomi to Present at Upcoming Scientific Meetings
Metagenomi to Present at Upcoming Scientific Meetings
- Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024
-在世界血友病联合会(WFH)世界大会上的口头陈述, 2024年4月23日
- Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024
-2024 年 5 月 8 日和 9 日美国基因与细胞疗法学会 (ASGCT) 2024 年年会上的两张海报
EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: a late breaking oral presentation at The World Federation of Hemophilia (WFH) World Congress, taking place April 21 – 24, 2024 in Madrid, Spain and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.
加利福尼亚州埃默里维尔,2024年4月8日(GLOBE NEWSWIRE)——致力于使用其专有的综合宏基因组学衍生基因编辑工具箱为患者开发治疗药物的精准基因医学公司Megenomi, Inc.(纳斯达克股票代码:MGX)今天宣布,该公司将出席即将举行的两次科学会议:在世界血友病联合会(WFH)世界大会上的最新口头演讲,将于 2024 年 4 月 21 日至 24 日在西班牙马德里举行,并在美国基因与细胞疗法学会举办了两场海报发布会(ASGCT) 2024 年年会将于 2024 年 5 月 7 日至 11 日在马里兰州巴尔的摩以虚拟方式举行。
WFH 2024 World Congress
Madrid, Spain
April 21-24, 2024
WFH 2024 世界大会
西班牙马德里
2024 年 4 月 21 日至 24 日
Oral Presentation Title: Metagenomi:
Potentially Curative Gene Editing Approach for Hemophilia A
Session: Late breaking session: New tech
Location: N103+N104
Date / time: Tuesday, April 23, 2024, 16:00 – 17:00 CEST
口头演讲题目:宏基因学:
A型血友病的潜在治疗基因编辑方法
会议:后期会议:新技术
地点:N103+N104
日期/时间:2024 年 4 月 23 日,星期二,欧洲中部标准时间 16:00 — 17:00
ASGCT 2024 Annual Meeting
Baltimore, MD
May 7-9, 2024
ASGCT 2024 年年会
马里兰州巴尔的摩
2024 年 5 月 7 日至 9 日
Poster Title: Novel CRISPR Effectors and Reverse Transcriptases Discovered from Metagenomics Enable Extensive Remodeling of the Human Genome
Abstract Number: 1209
Location: Exhibit Hall
Date / time: Thursday, May 9, 2024, 12:00 p.m. ET
海报标题:从宏基因组学中发现的新型 CRISPR 效应器和逆转录酶可实现对人类基因组的广泛重塑
摘要编号:1209
地点:展厅
日期/时间:美国东部时间 2024 年 5 月 9 日星期四下午 12:00
Poster Title: Novel and Efficient Base Editors Engineered to Comprehensively Target the Human Genome
Abstract Number: 684
Location: Exhibit Hall
Date / time: Wednesday, May 8, 2024, 12:00 p.m. ET
海报标题:专为全面靶向人类基因组而设计的新颖高效碱基编辑器
摘要编号:684
地点:展厅
日期/时间:美国东部时间 2024 年 5 月 8 日星期三下午 12:00
All presentations will be made available on the "News & Events," page in the Investors section of the Company's website at
所有演示文稿将在公司网站 “投资者” 部分的 “新闻与活动” 页面上公布
About Metagenomi
关于 Megenomi
Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases). Metagenomi believes its diverse and modular toolbox positions the company to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. For more information, please visit https://metagenomi.co.
Megenomi是一家精准基因药物公司,致力于使用其专有的综合宏基因组学衍生工具箱为患者开发治疗性疗法。Megenomi正在利用宏基因组学(研究从自然环境中回收的遗传物质)的力量来解锁40亿年的微生物进化,以发现和开发一套新颖的编辑工具,能够纠正基因组中任何地方发现的任何类型的基因突变。其全面的基因组编辑工具箱包括可编程核酸酶、碱基编辑器以及RNA和DNA介导的整合系统(包括主要编辑系统和聚类的定期间隔的短回文重复相关转座酶)。Metagenomi认为,其多样化的模块化工具箱使公司能够访问整个基因组,并选择最佳工具来释放患者基因组编辑的全部潜力。欲了解更多信息,请访问 https://metagenomi.co。
Cautionary Note Regarding Forward‐Looking Statements
关于前瞻性陈述的警示说明
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions, include, but are not limited to, any statements relating to our growth strategy and product development programs, including the timing of and our ability to conduct IND-enabling studies, make regulatory filings such as INDs and other applications and to obtain regulatory approvals for our product candidates, statements concerning the potential of therapies and product candidates, and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in "Risk Factors," in our most recent Form 10-K, on file with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
本新闻稿包含1933年《证券法》第27A条和1934年《证券交易法》第21E条所指的 “前瞻性陈述”,均经修订。此类陈述通常用 “预测”、“相信”、“可能”、“估计”、“预期”、“目标”、“打算”、“展望”、“可能”、“计划”、“潜力”、“预测”、“项目”、“应该”、“将” 和类似的表述来表示,包括但不限于与我们的增长战略相关的任何陈述以及产品开发计划,包括开展支持IND的研究、提交IND和其他申请等监管文件以及获得监管的时机和我们的能力对我们候选产品的批准、有关疗法和候选产品潜力的陈述,以及任何其他非历史事实的陈述。前瞻性陈述基于管理层当前的预期,受风险和不确定性的影响,这些风险和不确定性可能会对我们的业务、经营业绩、财务状况和股票价值产生负面影响。可能导致实际结果与当前预期结果存在重大差异的因素包括:与我们的增长战略相关的风险;我们获得、履行和维持融资和战略协议及关系的能力;与研发活动结果相关的风险;与开始和完成临床试验的时间相关的风险;与临床前和临床测试相关的不确定性;我们对第三方供应商的依赖;我们的吸引能力培养和留住关键人员;在开发产品的早期阶段;我们对大量额外资金的需求;政府监管;专利和知识产权事务;竞争;以及我们向美国证券交易委员会提交的最新10-K表中 “风险因素” 中描述的其他风险。除非法律要求,否则我们明确表示不承担任何义务或承诺公开发布此处包含的任何前瞻性陈述的任何更新或修订,以反映我们预期的任何变化或任何此类陈述所依据的事件、条件或情况的任何变化,并且我们要求1995年《私人证券诉讼改革法》中包含的前瞻性陈述受到安全港的保护。
Investor Contact:
Simon Harnest CIO, SVP Investor Relations
simon@metagenomi.co
投资者联系方式:
西蒙·哈内斯特首席信息官、投资者关系高级副总裁
simon@metagenomi.co
Media Contact:
Ashlye Hodge, Communications Manager
ashlye@metagenomi.co
媒体联系人:
Ashlye Hodge,传播经理
ashlye@metagenomi.co